What is Delve Bio?
Delve Bio operates at the intersection of high-throughput sequencing and clinical diagnostics. By leveraging metagenomic technologies, the company provides enterprise-level solutions designed to identify pathogens and complex biological signatures with unprecedented precision. As a key player in the medtech ecosystem, Delve Bio is currently transitioning from its foundational development phase into a robust scaling stage. Its market position is defined by its ability to translate complex genomic data into actionable clinical insights, a critical requirement for modern healthcare providers and research institutions seeking to improve patient outcomes through rapid, data-driven diagnostics.
How much funding has Delve Bio raised?
Delve Bio has raised a total of $35M across 1 funding round:
Series A
$35M
Series A (2023): $35M with participation from Section 32, GV, and Xontogeny Venture Fund II
Key Investors in Delve Bio
Section 32
A venture capital firm founded by Bill Maris that focuses on investing in cutting-edge technology and visionary entrepreneurs at the forefront of scientific advancement.
GV
A global venture capital firm that invests across multiple stages and sectors, with a strong emphasis on life sciences, enterprise solutions, and frontier technology innovations.
Xontogeny Venture Fund II
A specialized investment fund focused on supporting the development of life science companies and emerging biotechnology platforms.
What's next for Delve Bio?
With this recent capital backing, Delve Bio is poised to expand its commercial footprint and enhance its technological infrastructure. The strategic roadmap likely involves scaling its sequencing throughput and broadening its diagnostic portfolio to address unmet needs in infectious disease management. By aligning with high-profile venture partners, the company is well-positioned to navigate the complexities of the regulatory environment while accelerating the adoption of its metagenomic tools. Future growth will likely focus on deepening enterprise partnerships and solidifying its role as a standard-bearer for next-generation genomic diagnostics in the clinical setting.
See full Delve Bio company page
